InvestorsObserver
×
News Home

Is Inhibrx Inc (INBX) Stock at the Top of the Biotechnology Industry?

Monday, May 15, 2023 02:11 PM | InvestorsObserver Analysts

Mentioned in this article

Is Inhibrx Inc (INBX) Stock at the Top of the Biotechnology Industry?

A rating of 83 puts Inhibrx Inc (INBX) near the top of the Biotechnology industry according to InvestorsObserver. Inhibrx Inc's score of 83 means it scores higher than 83% of stocks in the industry. Inhibrx Inc also received an overall rating of 70, putting it above 70% of all stocks. Biotechnology is ranked 22 out of the 148 industries.

Overall Score - 70
INBX has an Overall Score of 70. Find out what this means to you and get the rest of the rankings on INBX!

What do These Ratings Mean?

Finding the best stocks can be tricky. It isn’t easy to compare companies across industries. Even companies that have relatively similar businesses can be tricky to compare sometimes. InvestorsObserver’s tools allow a top-down approach that lets you pick a metric, find the top sector and industry and then find the top stocks in that sector.
These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

What's Happening With Inhibrx Inc Stock Today?

Inhibrx Inc (INBX) stock is trading at $26.07 as of 2:10 PM on Monday, May 15, an increase of $1.34, or 5.42% from the previous closing price of $24.73. The stock has traded between $24.18 and $26.21 so far today. Volume today is low. So far 144,534 shares have traded compared to average volume of 417,929 shares. Click Here to get the full Stock Report for Inhibrx Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App